Valora Therapeutics, a San Diego, CA-based biotechnology company providing a novel approach to immunotherapy, raised $30M in Seed funding.
The round wad led by Avalon BioVentures, together with Bregua Corporation and TigerGene. Additional participation was provided by Alexandria Venture Investments and Correlation Ventures.
The company intends to use the funds to advance its proprietary AbLec platform to develop novel immunotherapeutics.
Led by Miguel Garcia-Guzman, Ph.D., CEO, Valora Therapeutics s a biotechnology company that provides a platform, AbLec (Antibody-Lectin chimera), that is expected to enhance the restoration of proper immunological competency. By precisely targeting specific sugar molecules on cells, it modulates glyco-immune checkpoints—a key control point in the body’s immune response. This approach holds the potential for developing therapeutics in oncology, autoimmune diseases, and other therapeutic areas.
Valora has established its R&D operations at the Avalon BioVentures Accelerator in San Diego, California, providing access to a supportive ecosystem of biotech experts and resources.
FinSMEs
20/11/2024